January 13, 2010 (Miami, Florida) — Aerosolized bronchodilators are independently associated with an increased risk for ventilator-associated pneumonia (VAP) in critically ill patients, according to ...

Patients with COPD also have a high prevalence of CVD. Bronchodilators prescribed for symptomatic COPD control may also contribute to cardiovascular risk. In accordance with treatment guidelines, most ...

And compared with the rest of the year, bronchodilator responsiveness was more common in winter months. HealthDay News — Patients are more likely to have positive bronchodilator responsiveness in the ...

Please provide your email address to receive an email when new articles are posted on . Spirometry testing in the afternoon vs. morning was linked to a decreased likelihood for bronchodilator ...

Novartis' dual combination bronchodilator Utibron Neohaler inhalation powder for patients with chronic obstructive pulmonary disease (COPD) has received FDA approval. It is not indicated to treat ...

A study of Korean patients with chronic obstructive pulmonary disease (COPD) found that a paradoxical response to short-acting bronchodilators may reduce lung function and quality of life. The study ...

A retrospective cohort study of <29-week-gestation infants with evolving BPD defined at age 28 days within the Pediatric Health Information System database. Controlling for observed confounding with ...

Researchers find a 28 percent greater risk of heart attack and stroke in older patients taking commonly prescribed drugs for chronic obstructive pulmonary disease (COPD). Canadian scientists are ...

Please provide your email address to receive an email when new articles are posted on . Bronchodilator responsiveness over 20% was linked to exacerbations and decreased prebronchodilator FEV 1. More ...

A new study reveals several new gene variants that are associated with how people living with chronic obstructive pulmonary disease respond to inhaled bronchodilators. A new study from Brigham and ...

August 16, 2010 — Nebulized hypertonic 3% saline solution without adjunctive bronchodilators has a low rate of adverse events in infants younger than 2 years with bronchiolitis, according to the ...